High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 4, 2012, Pages 232-239

  Kimura, Satoko ^a   Niwa, Yuka ^a   Iwajima, Yui ^b   Nagano, Yuko ^b   Yamamoto, Shohei ^b   Ohi, Yoshiaki ^a   Maeda, Yasuhiro ^b   Kurono, Yukihisa ^b   Ono, Hideki ^b   Haji, Akira ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PANCURONIUM BROMIDE;

AIR CONDITIONING; AIRFLOW; AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; BREATHING RATE; CARDIOPULMONARY ARREST; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; HYPOPNEA INDEX; HYPOTENSION; INTRAVENOUS ANESTHESIA; MALE; NONHUMAN; PHRENIC NERVE; PRIORITY JOURNAL; RAT; TRACHEA; VAGOTOMY;

ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; RATS; RATS, WISTAR; RESPIRATION; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RESPIRATORY RATE; VAGOTOMY;

ANIMALIA; RATTUS;

EID: 84866527346     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00889.x     Document Type: Article

References (36)

1. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L et al.Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006;319:1477-84.
2. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37:471-84.
3. Chang Q, Chow MS, Zuo Z. Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method. Biomed Chromatogr 2009;23:852-7.
4. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-50.
5. Okamoto E. Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan. Expert Rev Pharmacoecon Outcomes Res 2010;10:17-24.
6. Pharmaceuticals and Medical Devices Agency. Urgent safety information for Tamiflu, March 2007, http://www.info.pmda.go.jp/kinkyu_anzen/file/kinkyu20070320.pdf (in Japanese).
7. MLHW (Ministry of Health, Labor and Welfare, Japan). Public opening data (documents 9-1) at the Meeting for Safety Measure Investigation Council, held June 16, 2009, http://www.mhlw.go.jp/shingi/2009/06/dl/s0616-4ac.pdf (in Japanese).
8. MLHW (Ministry of Health, Labor and Welfare, Japan). Public opening data (documents 3-4) at the Meeting for Safety Measure Investigation Council, held August 25, 2010, http://www.mhlw.go.jp/stf/shingi/2r9852000000n6tv-att/2r9852000000n7o9.pdf (in Japanese).
9. Izumi Y, Tokuda K, O'dell KA, Zorumski CF, Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 2007;426:54-8.
10. Izumi Y, Tokuda K, O'Dell K, Zorumski C, Narahashi T. Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants. Hum Exp Toxicol 2008;27:911-7.
11. Usami A, Sasaki T, Satoh N, Akiba T, Yokoshima S, Fukuyama T et al. Oseltamivir enhances hippocampal network synchronization. J Pharmacol Sci 2008;106:659-62.
12. Suzuki M, Masuda Y. Effect of a neuraminidase inhibitor (oseltamivir) on mouse jump-down behavior via stimulation of dopamine receptors. Biomed Res 2008;29:233-8.
13. Yoshino T, Nisijima K, Shioda K, Yui K, Kato S. Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci Lett 2008;438:67-9.
14. Ono H, Nagano Y, Matsunami N, Sugiyama S, Yamamoto S, Tanabe M. Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice: comparison among oseltamivir, zanamivir and diclofenac. Biol Pharm Bull 2008;31:638-42.
15. FDA/Center. Label Approval History, Tamiflu, FDA/Center for Drug Evaluation and Research, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s056_021246s039lbl.pdf.
16. Freichel C, Breidenbach A, Hoffmann G, Körner A, Gatti S, Donner B et al. Absence of central nervous system and hypothermic effects following single oral administration of high doses of oseltamivir in the rat. Basic Clin Pharmacol Toxicol 2012; doi: 10.1111/j.1742-7843.2012.00861.x. [Epub ahead of print]
17. von Euler C. Brain stem mechanisms for generation and control of breathing pattern. In: Cherniack NS, Widdicombe JG. (eds). Handbook of Physiology, Sect. 3, The Respiratory System, Vol. II, Control of Breathing. American Physiological Society, Bethesda, 1986;1-67.
18. Richter DW. Neuronal regulation of respiration: rhythmogenesis and afferent control. In: Greger R, Windhorst U (eds). Comprehensive Human Physiology. Vol. 2. Springer, Berlin, 1996;2079-95.
19. Haji A, Takeda R, Okazaki M. Neuropharmacology of control of respiratory rhythm and pattern in mature mammals. Pharmacol Ther 2000;86:277-304.
20. Vocci F, Farber T. Extrapolation of animal toxicity data to man. Regul Toxicol Pharmacol 1988;8:389-98.
21. Pharmaceuticals and Medical Devices Agency. Public assessment report, 2000, http://www.info.pmda.go.jp/shinyaku/shinyaku_previous_index.html (in Japanese).
22. Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother 2008;52:3687-93.
23. 11C]Ro 64-0802 in mice. Nucl Med Biol 2009;36:47-55.
24. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M et al. Limited brain distribution of [3R, 4R, 5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 2009;37:315-21.
25. Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos 2008;36:6-9.
26. Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 2009;53:4753-61.
27. Aiba H, Mochizuki M, Kimura M, Hojo H. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology 2001;57:295-9.
28. Yang J, Shi D, Yang D, Song X, Yan B. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol 2007;2:686-94.
29. Fernandez C, Buyse M, German-Fattal M, Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharmceut Sci 2004;7:359-71.
30. Yokota S, Imagawa T, Miyamae T, Ito S, Nakajima S, Nezu A et al. Hypothetical pathophysiology of acute encephalopathy and encephalitis related to influenza virus infection and hypothermia therapy. Pediatr Int 2000;42:197-203.
31. Sharma HS, Westman J, Nyberg F. Pathophysiology of brain edema and cell changes following hyperthermic brain injury. Prog Brain Res 1998;115:351-412.
32. Wang S, Le TQ, Kurihara N, Chida J, Cisse Y, Yano M et al. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 2010;202:991-1001.
33. Oshima S, Nemoto E, Kuramochi M, Saito Y, Kobayashi D. Penetration of oseltamivir and its metabolite into the brain after lipopolysaccharide-induced inflammation in mice. J Pharm Pharmacol 2009;61:1397-400.
34. Ose A, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T et al. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos 2008;36:427-34.
35. 11C]oseltamivir using PET and autoradiography. Neurosci Lett 2011;495:187-91.
36. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 2009;77:238-47.